Shinji Takeuchi

List of Publications by Year
in descending order

48	1,618	361296 20	302012 39
papers	citations	h-index	g-index

48	48	48	2419
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab. Internal Medicine, 2022, 61, 75-79.	0.3	0
2	Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review. Internal Medicine, 2022, 61, 1735-1738.	0.3	3
3	STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis. Npj Precision Oncology, 2022, 6, 11.	2.3	8
4	Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1â€rearranged tumor cells. Cancer Science, 2022, 113, 2323-2335.	1.7	5
5	Methylation of Tumor Suppressive miRNAs in Plasma from Patients With Pancreaticobiliary Diseases. Cancer Diagnosis & Prognosis, 2022, 2, 378-383.	0.3	1
6	Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression. Clinical Cancer Research, 2021, 27, 1410-1420.	3.2	24
7	Multiple Malignant Lymphomas of the Bile Duct Developing after Spontaneous Regression of an Autoimmune Pancreatitis-like Mass. Internal Medicine, 2021, 60, 409-415.	0.3	1
8	Multi-institutional survey of cancer disparities in disabled patients in the region of northwestern Japan. International Journal of Clinical Oncology, 2021, 26, 1009-1014.	1.0	6
9	Trametinib overcomes KRASâ€G12Vâ€“induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFRâ€mutant lung cancer. Cancer Science, 2021, 112, 3784-3795.	1.7	12
10	Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET). Translational Lung Cancer Research, 2021, 10, 314-325.	1.3	13
11	A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. Lung Cancer, 2021, 162, 140-146.	0.9	32
12	MET amplification results in heterogeneous responses to osimertinib in EGFRâ€mutant lung cancer treated with erlotinib. Cancer Science, 2020, 111, 3813-3823.	1.7	9
13	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nature Communications, 2020, 11, 4607.	5.8	69
14	Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report. BMC Cancer, 2020, 20, 156.	1.1	6
15	Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged LungÂCancer. Journal of Thoracic Oncology, 2020, 15, 752-765.	0.5	24
16	Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma. Oxford Medical Case Reports, 2020, 2020, omaa116.	0.2	2
17	Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation doubleâ€positive lung cancer. Cancer Science, 2020, 111, 561-570.	1.7	31
18	Glycogen synthase kinaseâ€3 inhibition overcomes epithelialâ€mesenchymal transitionâ€associated resistance to osimertinib in EGFRâ€mutant lung cancer. Cancer Science, 2020, 111, 2374-2384.	1.7	17

#	Article	IF	Citations
19	Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with <i>BIM</i> deletion polymorphism. Journal of Medical Investigation, 2020, 67, 343-350.	0.2	3
20	Aberrant Methylation of Tumor Suppressive miRNAs in Bile from Patients With Pancreaticobiliary Diseases. Anticancer Research, 2019, 39, 5449-5459.	0.5	6
21	Patientâ€derived xenograft models of nonâ€small cell lung cancer for evaluating targeted drug sensitivity and resistance. Cancer Science, 2019, 110, 3215-3224.	1.7	32
22	Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. Molecular Cancer Therapeutics, 2019, 18, 947-956.	1.9	14
23	Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status. Cancer Research, 2019, 79, 1658-1670.	0.4	79
24	AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nature Communications, 2019, 10, 259.	5.8	223
25	Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusionâ€“Positive Tumor Cells in a Brain Metastasis Model. Clinical Cancer Research, 2018, 24, 2357-2369.	3.2	25
26	Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report. BMC Pulmonary Medicine, 2018, 18, 193.	0.8	12
27	Notch3-dependent Î²-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. Nature Communications, 2018, 9, 3198.	5.8	61
28	Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinibâ€resistance of <scp>EML</scp>4â€<scp>ALK</scp> lung cancer and circumvention by epidermal growth factor receptor inhibitors. Cancer Science, 2017, 108, 53-60.	1.7	28
29	MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer. Molecular Cancer Therapeutics, 2017, 16, 506-515.	1.9	52
30	Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation. Cancer Science, 2017, 108, 696-703.	1.7	15
31	Impact of <scp>MET</scp> inhibition on smallâ€cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/<scp>MET</scp> pathway. Cancer Science, 2017, 108, 1378-1385.	1.7	20
32	Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphismâ€“Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer. Clinical Cancer Research, 2017, 23, 3139-3149.	3.2	69
33	In vivo imaging xenograft models for the evaluation of antiâ€brain tumor efficacy of targeted drugs. Cancer Medicine, 2017, 6, 2972-2983.	1.3	2
34	Phase I/II study of alectinib in lung cancer with <i>RET</i> fusion gene: study protocol. Journal of Medical Investigation, 2017, 64, 317-320.	0.2	16
35	Phase I study of combined therapy with vorinostat and gefitinib to treat <i>BIM</i> deletion polymorphism-associated resistance in <i>EGFR</i>-mutant lung cancer (VICTROY-J): a study protocol. Journal of Medical Investigation, 2017, 64, 321-325.	0.2	7
36	In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET. Oncotarget, 2017, 8, 73766-73773.	0.8	10

#	Article	IF	Citations
37	Recurrence of renal cell carcinoma diagnosed using contralateral adrenal biopsy with endoscopic ultrasound-guided fine-needle aspiration. Molecular and Clinical Oncology, 2016, 4, 537-540.	0.4	1
38	Organâ€specific efficacy of <scp>HSP</scp>90 inhibitor in multipleâ€organ metastasis model of chemorefractory small cell lung cancer. International Journal of Cancer, 2016, 138, 1281-1289.	2.3	14
39	High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. Oncotarget, 2016, 7, 3847-3856.	0.8	56
40	In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human <scp>EML</scp>4â€<scp>ALK</scp> lung cancer cell line. Cancer Science, 2015, 106, 244-252.	1.7	32
41	Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma. Cancer Research, 2015, 75, 4188-4197.	0.4	16
42	Development of Therapy for Overcoming EGFR-TKI Resistance due to BIM Polymorphisms. Japanese Journal of Lung Cancer, 2015, 55, 941-947.	0.0	0
43	Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: Sensitivity and resistance. Respiratory Investigation, 2014, 52, 348-356.	0.9	15
44	EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition. Cancer Research, 2013, 73, 2428-2434.	0.4	151
45	Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors. PLoS ONE, 2013, 8, e84700.	1.1	41
46	Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells. Clinical Cancer Research, 2012, 18, 3592-3602.	3.2	104
47	Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer. American Journal of Pathology, 2012, 181, 1034-1043.	1.9	55
48	Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort. Journal of Thoracic Oncology, 2011, 6, 2011-2017.	0.5	196